Tymchuk Christopher N, Hartiala Jaana, Patel Pragna I, Mehrabian Margarete, Allayee Hooman
Institute for Genetic Medicine, USC Keck School of Medicine, University of Southern California, 2250 Alcazar Street, IGM 240, Los Angeles, CA 90089-9075, USA.
Curr Atheroscler Rep. 2006 May;8(3):184-92. doi: 10.1007/s11883-006-0072-2.
Despite numerous advances made in identifying the genes for rare mendelian forms of cardiovascular disease (CVD), relatively little is known about the common, complex forms at the genetic level. Moreover, most genes that have been associated with CVD, whether they are single gene forms or more common forms of the disease, have primarily been involved in biochemical pathways related to what are considered "conventional" risk factors. However, recent genetic studies have begun to identify genes and pathways associated with CVD that would not be considered to underlie conventional risk factors. In this review, we discuss the evidence for this latter notion based on recent linkage and association studies in humans. As an example, we also illustrate how a combination of mouse and human genetics led to identification of the 5-lipoxygenase pathway for CVD, with potentially important implications for its treatment and diagnosis. We conclude with a discussion of the prospects for identifying CVD genes in the future and for potentially developing more effective therapeutic strategies.
尽管在确定罕见孟德尔形式心血管疾病(CVD)的基因方面取得了诸多进展,但在基因层面上,对于常见的复杂形式CVD却知之甚少。此外,大多数与CVD相关的基因,无论它们是单基因形式还是该疾病更常见的形式,主要都涉及与被视为“传统”风险因素相关的生化途径。然而,最近的基因研究已开始鉴定与CVD相关的基因和途径,而这些基因和途径并不被认为是传统风险因素的基础。在本综述中,我们基于最近在人类中的连锁和关联研究来讨论后一种观点的证据。作为一个例子,我们还阐述了小鼠遗传学和人类遗传学的结合如何促成了对CVD的5-脂氧合酶途径的鉴定,这对其治疗和诊断可能具有重要意义。我们最后讨论了未来鉴定CVD基因以及潜在开发更有效治疗策略的前景。